Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 11/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 11/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 11/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 7/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL29833189 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL30282088 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL2203716 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29363193 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787407 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL29945090 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL31048740 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL26433 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29546835 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL28305816 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265754-A | Additive composition for antifouling coating | 阿萨达有限责任公司 | 2024-06-28 | — | — | CN | claimed |
| CN-115851097-A | Preparation method of porous liquid injected photoresponse super-lubricating antifouling paint | 浙江大学 | 2023-03-28 | — | — | CN | claimed |
| CN-113214434-B | Preparation of core-shell acrylic acid antifouling resin and application of core-shell acrylic acid antifouling resin in copper-free antifouling paint | 浙江大学 | 2022-04-01 | — | — | CN | claimed |
| CN-112574631-B | Novel marine antifouling paint composition based on nano microcapsule controlled release technology | 浙江大学 | 2022-02-18 | — | — | CN | claimed |
| EP-3339387-B1 | COMPOUNDS BASED ON OF ADDUCTS WITH ISOCYANATES FOR COATING COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2020-06-24 | — | — | EP | claimed |
| CN-108218909-A | For the compound based on the adduct with isocyanates of coating composition | 赢创德固赛有限公司 | 2018-06-29 | — | — | CN | claimed |
| US-20180179234-A1 | COMPOUNDS BASED ON ADDUCTS WITH ISOCYANATES FOR COATING COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2018-06-28 | — | — | US | claimed |
| EP-3339387-A1 | COMPOUNDS BASED ON OF ADDUCTS WITH ISOCYANATES FOR COATING COMPOSITIONS | Evonik Degussa GmbH (DE) | 2018-06-27 | — | — | EP | claimed |
| EP-2079706-B1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS JSC (LV) | 2011-07-20 | — | — | EP | claimed |
| US-7902377-B2 | Method for preparing medetomidine and its salts | JSC GRINDEKS (LV) | 2011-03-08 | — | — | US | claimed |
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-02-25 | — | — | US | claimed |
| EP-2079706-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | Grindeks, a joint stock company (LV) | 2009-07-22 | — | — | EP | claimed |
| WO-2008055852-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2008-05-15 | — | — | WO | claimed |
| EP-1918282-A1 | Method for preparing medetomidine and its salts | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | claimed |
| US-12501899-B2 | Mite infestation treatment | VETO-PHARMA (FR) | 2025-12-23 | — | — | US | disclosed |
| US-20240342137-A1 | COMPOSITIONS OF ALPHA-2 ANTAGONISTS AND METHODS AND USES THEREOF | HO RODNEY J Y (US) | 2024-10-17 | — | — | US | disclosed |
| CN-118265754-A | Additive composition for antifouling coating | 阿萨达有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| US-7902377-B2 | Method for preparing medetomidine and its salts | JSC GRINDEKS (LV) | 2011-03-08 | — | — | US | disclosed |
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | GRINDEKS A JOINT STOCK COMPANY (LV) | 2010-02-25 | — | — | US | disclosed |
| EP-1918282-A1 | Method for preparing medetomidine and its salts | "Joint Stock Company Grindeks" (LV) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179234-A1 | COMPOUNDS BASED ON ADDUCTS WITH ISOCYANATES FOR COATING COMPOSITIONS | DNMT1, MGMT, TET3 | ADRA2A 4538/4885ADRA2B 4655/4885ADRA2C 4346/4885 |
| US-20100048915-A1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS. | ADRB2, ADRB3, OPRM1 | ADRA2A 15/4885ADRA2B 6/4885ADRA2C 5/4885 |
| US-12501899-B2 | Mite infestation treatment | RHOA, NPEPPS, TUBA3E | ADRA2A 3402/4885ADRA2B 3269/4885ADRA2C 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.